On 10–11 January 2026, the China Respiratory Conference 2026 was held grandly in Beijing. With the theme "Building a Resilient Care System for Infectious Respiratory Diseases", the event brought together 460+ experts and scholars in respiratory medicine and related disciplines, including Wang Chen, Qu Jieming, Song Yuanlin, Dai Huaping, and other leading figures. As an innovative medical approach, Asclepius Meditec was invited to participate, attracting significant attention from researchers and clinicians!
2026 China Respiratory Medicine Development Conference
On the morning of 10 January, the China Respiratory Conference 2026 commenced in Beijing with an opening address by Academician Wang Chen, Director of the National Respiratory Medicine Centre and Chairman of the conference.
Academician Wang Chen delivered the keynote speech of the conference
Regarding the specific content of the conference theme, top experts from various disciplines were invited to present their insights in the form of special reports. In the subsequent discussion session, the participating experts further engaged in in-depth discussions on the conference theme.
Of particular note is that many of the scholars attending this grand event have been deeply involved in hydrogen-oxygen medical research for many years, participating in numerous core research projects and making significant contributions to innovative breakthroughs in this field.
Professor Qu Jieming delivered a speech
Professor Qu Jieming is the Party Secretary of Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine, Director of the Shanghai Key Laboratory of Emergency Prevention, Control and Treatment of Respiratory Infectious Diseases, and Director of the Institute of Respiratory Diseases at Shanghai Jiao Tong University School of Medicine.
Professor Qu Jieming from Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine (one of the top ten public hospitals in China in terms of overall strength) led a prospective, multi-center, randomized controlled clinical trial with Professor Zhang Wenhong to evaluate the efficacy and safety of hydrogen-oxygen inhalation therapy as an adjunct treatment for COVID-19. The paper has been published [1]. The results of this study showed that compared to oxygen therapy alone, hydrogen-oxygen inhalation shortened the time to viral clearance, reduced inflammatory cytokine levels, and alleviated lung lesions, thus reducing the occurrence of early severe cases.
Professor Song Yuanlin delivered a speech
Professor Song Yuanlin is the Director of the Department of Respiratory and Critical Care Medicine at Zhongshan Hospital affiliated with Fudan University and the Deputy Director of the Shanghai Institute of Respiratory Diseases.
Professor Song Yuanlin of Zhongshan Hospital affiliated with Fudan University in Shanghai (one of the top ten public hospitals in China in terms of overall strength) is one of the researchers involved in the clinical research of hydrogen-oxygen therapy for chronic obstructive pulmonary disease (COPD). He participated in the research on the indications and post-market studies of the Asclepius Meditec hydrogen-oxygen therapy machine.
Professor Dai Huaping delivered a speech
Professor Dai Huaping is the Deputy Director of the National Respiratory Medicine Center and the Director of the Third Department of Respiratory and Critical Care Medicine at China-Japan Friendship Hospital.
Professor Dai Huaping of China-Japan Friendship Hospital (one of the top 20 public hospitals in China in terms of overall strength) has published a paper on the improvement of pulmonary fibrosis through hydrogen-oxygen inhalation [2]. This study showed that hydrogen inhalation alleviates pulmonary fibrosis by inhibiting TGF-β1.
Asclepius Meditec’s medical hydrogen-oxygen generator series, as an innovative medical approach, has shown remarkable effectiveness in the prevention and treatment of respiratory diseases. It was invited to participate in the 2026 China Respiratory Medicine Development Conference, attracting the attention of numerous experts and scholars.
Asclepius Meditec Booth
Asclepius Meditec's medical hydrogen-oxygen generator series is the only hydrogen-oxygen inhalation device globally approved as a Class III medical device. In 2017, it was listed as a "National Innovation" respiratory medical device by the China National Medical Products Administration (NMPA). In 2020, it received its first Class III medical device certificate (Registration Number: 20203080066). In 2023, it received its second Class III medical device certificate (Registration Number: 20233081929).
Asclepius Meditec's medical hydrogen-oxygen generators were displayed at the conference venue.
In November 2025, the International Society for Hydrogen Medicine and Biology (ISHMB) awarded Mr. Lin Hsin-Yung, founder of Asclepius Meditec, the "ISHMB Industrial Innovation Breakthrough Award" to recognize Asclepius Meditec’s pioneering achievement in developing the world's first medical hydrogen-oxygen generator.
ISHMB Industry Innovation Breakthrough Award" Certificate
At the conference venue, the experience area for Asclepius Meditec's medical hydrogen-oxygen generators was bustling with people, and numerous experts, scholars, and medical professionals personally tried the product. Many experts specializing in respiratory medicine commented after their experience that Asclepius Meditec provides new ideas and tools for the prevention and treatment of respiratory diseases.
Attendees experienced the Asclepius Meditec's medical hydrogen-oxygen generators
Recently, a Phase IV clinical study led by the National Clinical Research Center for Respiratory Diseases showed that hydrogen-oxygen inhalation therapy can reduce the frequency of acute exacerbations of chronic obstructive pulmonary disease (COPD) by 80%. Asclepius Meditec has earned industry recognition through its proven effectiveness.
In the future, as research into hydrogen-oxygen medicine continues to deepen and its clinical applications expand, Asclepius Meditec will continue to collaborate with colleagues in the respiratory field, empowering respiratory healthcare with innovative technologies. We will contribute more to improving the care system for infectious respiratory diseases and enhancing the respiratory health of the entire population, ensuring that cutting-edge medical advancements better benefit a wider range of patients.
References：
